Anti‐Oxidative and Anti‐Inflammatory Micelles: Break the Dry Eye Vicious Cycle
Top Cited Papers
Open Access
- 18 April 2022
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 9 (17) , e2200435
Abstract
Dry eye disease (DED) impacts ≈30% of the world's population and causes serious ocular discomfort and even visual impairment. Inflammation is one core cause of the DED vicious cycle, a multifactorial deterioration in DED process. However, there are also reactive oxygen species (ROS) regulating inflammation and other points in the cycle from the upstream, leading to treatment failure of current therapies merely targeting inflammation. Accordingly, the authors develop micelle‐based eye drops (more specifically p38 mitogen‐activated protein kinases (MAPK) inhibitor Losmapimod (Los)‐loaded and ROS scavenger Tempo (Tem)‐conjugated cationic polypeptide micelles, designated as MTem/Los) for safe and efficient DED management. Cationic MTem/Los improve ocular retention of conjugated water‐soluble Tem and loaded water‐insoluble Los via electrostatic interaction with negatively charged mucin on the cornea, enabling an increase in therapeutic efficiency and a decrease in dosing frequency. Mechanistically, MTem/Los effectively decrease ROS over‐production, reduce the expression of proinflammatory cytokines and chemokines, restrain macrophage proinflammatory phenotypic transformation, and inhibit cell apoptosis. Therapeutically, the dual‐functional MTem/Los suppress the inflammatory response, reverse corneal epithelial defect, save goblet cell dysfunction, and recover tear secretion, thus breaking the vicious cycle and alleviating the DED. Moreover, MTem/Los exhibit excellent biocompatibility and tolerability for potential application as a simple and rapid treatment of oxidative stress‐ and inflammation‐induced disorders, including DED.Keywords
Funding Information
- National Key Research and Development Program of China (2020YFE0204400, 2018YFC1106104)
- National Natural Science Foundation of China (22005265, 82070939, 22105126, 81870641)
- Natural Science Foundation of Shanghai Municipality (22ZR1433500)
This publication has 63 references indexed in Scilit:
- Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trialThe Lancet, 2014
- Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trialThe Lancet Respiratory Medicine, 2014
- Spdef Null Mice Lack Conjunctival Goblet Cells and Provide a Model of Dry EyeThe American Journal of Pathology, 2013
- Nuclear Factor-κB: Central Regulator in Ocular Surface Inflammation and DiseasesThe Ocular Surface, 2012
- Therapeutic Targeting of Mitochondrial Superoxide in HypertensionCirculation Research, 2010
- Preservatives in eyedrops: The good, the bad and the uglyProgress in Retinal and Eye Research, 2010
- Synthesis and property of poly(sodium 4-styrenesulfonate) grafted chitosan by nitroxide-mediated polymerization with chitosan-TEMPO macroinitiatorCarbohydrate Polymers, 2010
- p38MAPK: stress responses from molecular mechanisms to therapeuticsTrends in Molecular Medicine, 2009
- Dry Eye with Only Decreased Tear Break-up Time is Sometimes Associated with Allergic ConjunctivitisOphthalmology, 1995
- Basic Tear FlowOphthalmology, 1980